Roche Shelves Phase III Huntington's Candidate Tominersen
Follows Independent Committee Data Review
Roche’s Phase III of tominersen in Huntington's disease has been stopped after an independent interim review, but with no new or emerging safety signals reported, analysts presume efficacy was the problem.
You may also be interested in...
Deal Snapshot: Roche gene therapy subsidiary Spark gets option and will partner with start-up NeuExcell on a Huntington’s gene therapy that researchers say may regenerate functional neurons.
While many other approaches have failed, Ionis and Biogen hope their novel oligonucleotide can stop toxic tau tangles forming in the brain.
Small-molecule drug delivery tech could help Ionis deliver its oligonucleotides where others cannot reach.